Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma

ABSTRACT: Endocrinologically active pituitary adenomas are treated either with surgery, radiotherapy or various drugs, including dopamine agonists, long-acting somatostatin analogs, growth hormone receptor antagonists, or corticosteroid secretion inhibitors. Fully 35% to 55% of pituitary adenomas invade adjacent structures. This figure is lower in gonadotroph adenomas, less than 5% compared to other adenoma types. Clinical management of invasive adenomas is challenging, and most of them tend to recur after surgery.

• Autores: Ortiz Gómez, León Darío; Syro Moreno, Luis Vicente; Ersen, Ayca; Penagos, Luis C.; Uribe, Humberto; Scheithauer, Bernd W.; Rotondo, Fabio; Horvath, Eva; Kovacs, Kalman
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2014
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/39509
• Acceso en línea: https://hdl.handle.net/10495/39509
• Palabra clave: Temozolomida; Temozolomide; Adenoma; Adenoma - cirugía; Adenoma - tratamiento farmacológico; Adenoma - radioterapia; https://id.nlm.nih.gov/mesh/D000077204; https://id.nlm.nih.gov/mesh/D000236
• Rights: openAccess
• License: https://creativecommons.org/licenses/by-nc-nd/4.0/